Summary
90.12 3.66(4.23%)05/15/2024
Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (EW)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 0.92 | 1.46 | -7.05 | -0.89 | 29.05 | -3.55 | 44.44 | 6,144.36 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 85.86 | |
| Open | 85.60 | |
| High | 86.19 | |
| Low | 85.01 | |
| Volume | 1,394,050 | |
| Change | 0.78 | |
| Change % | 0.92 | |
| Avg Volume (20 Days) | 2,333,030 | |
| Volume/Avg Volume (20 Days) Ratio | 0.60 | |
| 52 Week Range | 60.57 - 96.10 | |
| Price vs 52 Week High | -10.66% | |
| Price vs 52 Week Low | 41.75% | |
| Range | 0.30 | |
| Gap Up/Down | -0.40 | |
Fundamentals | ||
| Market Capitalization (Mln) | 54,330 | |
| EBIDTA | 1,920,099,968 | |
| PE Ratio | 37.3793 | |
| PEG Ratio | 5.1879 | |
| WallStreet Target Price | 95.52 | |
| Book Value | 11.8160 | |
| Earnings Per Share | 2.3200 | |
| EPS Estimate Current Quarter | 0.6400 | |
| EPS Estimate Next Quarter | 0.7000 | |
| EPS Estimate Current Year | 2.7600 | |
| EPS Estimate Next Year | 3.1200 | |
| Diluted EPS (TTM) | 2.3200 | |
| Revenues | ||
| Profit Marging | 0.2301 | |
| Operating Marging (TTM) | 0.2739 | |
| Return on asset (TTM) | 0.1205 | |
| Return on equity (TTM) | 0.2128 | |
| Revenue TTM | 6,143,399,936 | |
| Revenue per share TTM | 10.1510 | |
| Quarterly Revenue Growth (YOY) | 0.0950 | |
| Quarterly Earnings Growth (YOY) | 0.0360 | |
| Gross Profit (TTM) | 4,303,600,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 37.3793 | |
| Forward PE | 32.8947 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 8.1717 | |
| Revenue Enterprise Value | 8.8916 | |
| EBITDA Enterprise Value | 30.3262 | |
| Shares | ||
| Shares Outstanding | 602,600,000 | |
| Shares Float | 596,561,948 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.02 | |
| Insider (%) | 0.90 | |
| Institutions (%) | 84.32 | |
05/13 10:11 EST - reuters.com
Edwards Lifesciences hit with Meril's EU antitrust complaint
U.S. heart valve maker Edwards Lifesciences has been hit with an EU antitrust complaint by Indian rival Meril including for allegedly anti-competitive practices related to patents, a move that could bolster EU regulators' scrutiny of Edwards.
Edwards Lifesciences hit with Meril's EU antitrust complaint
U.S. heart valve maker Edwards Lifesciences has been hit with an EU antitrust complaint by Indian rival Meril including for allegedly anti-competitive practices related to patents, a move that could bolster EU regulators' scrutiny of Edwards.
05/07 12:41 EST - zacks.com
ALC vs. EW: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?
ALC vs. EW: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Alcon (ALC) and Edwards Lifesciences (EW). But which of these two stocks presents investors with the better value opportunity right now?
05/01 10:46 EST - zacks.com
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
Here is how Edwards Lifesciences (EW) and SNDL Inc. (SNDL) have performed compared to their sector so far this year.
05/01 10:35 EST - zacks.com
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
The heavy selling pressure might have exhausted for Edwards Lifesciences (EW) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
04/30 09:56 EST - zacks.com
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
04/29 13:20 EST - zacks.com
Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
Explore how Edwards Lifesciences' (EW) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.
04/26 12:11 EST - zacks.com
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
Edwards Lifesciences (EW) Q1 Earnings Top, 2024 Sales View Up
Strong performance of SAPIEN 3 Ultra RESILIA platform and sustainable TAVR growth drives Edwards Lifesciences (EW) Q1 revenues.
04/25 21:19 EST - seekingalpha.com
Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q1 2024 Earnings Conference Call April 25, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader of TMTT Larry Wood - Group President of TAVR and Surgical Structural Heart Katie Szyman - Global Leader of Critical Care Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Matt Taylor - Jefferies Joanne Wuensch - Citi Matt Miksic - Barclays Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Philip Chickering - Deutsche Bank Richard Newitter - Truist Securities Danielle Antalffy - UBS Joshua Jennings - TD Cowen Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2024 Results. At this time, all participants are in a listen-only mode.
Edwards Lifesciences Corporation (EW) Q1 2024 Earnings Call Transcript
Edwards Lifesciences Corporation (NYSE:EW ) Q1 2024 Earnings Conference Call April 25, 2024 5:00 PM ET Company Participants Mark Wilterding - SVP & IR Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - Global Leader of TMTT Larry Wood - Group President of TAVR and Surgical Structural Heart Katie Szyman - Global Leader of Critical Care Conference Call Participants Robbie Marcus - JPMorgan Travis Steed - Bank of America Larry Biegelsen - Wells Fargo Matt Taylor - Jefferies Joanne Wuensch - Citi Matt Miksic - Barclays Shagun Singh - RBC Capital Markets Chris Pasquale - Nephron Research Philip Chickering - Deutsche Bank Richard Newitter - Truist Securities Danielle Antalffy - UBS Joshua Jennings - TD Cowen Operator Greetings, and welcome to the Edwards Lifesciences First Quarter 2024 Results. At this time, all participants are in a listen-only mode.
04/25 19:01 EST - zacks.com
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Compared to Estimates, Edwards Lifesciences (EW) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
04/25 18:30 EST - zacks.com
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
Edwards Lifesciences (EW) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.62 per share a year ago.
Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
Edwards Lifesciences (EW) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.64 per share. This compares to earnings of $0.62 per share a year ago.
04/25 18:29 EST - reuters.com
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength
Edwards Lifesciences Corp on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices.
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength
Edwards Lifesciences Corp on Thursday reported upbeat first-quarter profit due to strong demand for its artificial heart valves and other medical devices.
04/25 16:31 EST - investors.com
Edwards Lifesciences Nabs Quarterly Beat And Plans A 'Critical' Spinoff
Edwards Lifesciences stock was muted late Thursday after the company beat first-quarter calls and gave more color into a looming spinoff.
Edwards Lifesciences Nabs Quarterly Beat And Plans A 'Critical' Spinoff
Edwards Lifesciences stock was muted late Thursday after the company beat first-quarter calls and gave more color into a looming spinoff.
04/25 16:15 EST - businesswire.com
Edwards Lifesciences Reports First Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT.
Edwards Lifesciences Reports First Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended March 31, 2024. Highlights and Outlook Q1 sales grew 10% on a reported and constant currency1 basis to $1.6 billion Q1 TAVR sales grew 6%; constant currency sales grew 8% adjusted for billing days Q1 TMTT sales grew 75% Q1 EPS of $0.58; adjusted1 EPS of $0.66 Raising 2024 sales guidance to the high end of previous 8 to 10%1 range Raising full-year 2024 sales guidance for TMTT.
04/24 15:01 EST - zacks.com
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
Here is a sneak peek into how the three major MedTech stocks, LH, EW and RMD, are expected to fare in their quarterly results slated to be released tomorrow.
04/22 10:22 EST - zacks.com
Unveiling Edwards Lifesciences (EW) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Unveiling Edwards Lifesciences (EW) Q1 Outlook: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
04/19 08:50 EST - zacks.com
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
5 Large-Cap Medical Stocks to Buy Ahead of Q1 Earnings
We have narrowed our search to five S&P 500 medical stocks that are poised to beat on first-quarter earnings results.These are: HCA, UHS, LH, EW, PODD.
04/18 11:07 EST - zacks.com
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Edwards Lifesciences (EW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/18 07:10 EST - businesswire.com
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L.
Edwards Lifesciences to Host Earnings Conference Call on April 25, 2024
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended March 31, 2024 after the market closes on Thursday, April 25, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards L.
04/17 12:05 EST - zacks.com
Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?
The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.
Is a Beat Likely for Edwards Lifesciences (EW) in Q1 Earnings?
The strong adoption of transcatheter heart valves is expected to have led to Edwards Lifesciences' (EW) growth in the first quarter.
04/16 12:41 EST - zacks.com
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Edwards Lifesciences (EW). But which of these two companies is the best option for those looking for undervalued stocks?
ITGR vs. EW: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Instruments stocks have likely encountered both Integer (ITGR) and Edwards Lifesciences (EW). But which of these two companies is the best option for those looking for undervalued stocks?